Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs Centrus Energy Corp (LEU) Price & Performance

Abeona Therapeutics IncTrade
Centrus Energy CorpTrade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs Centrus Energy Corp — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Centrus Energy Corp trades at $185.86 (market cap $3.77B). The key difference: Centrus Energy Corp is far larger — about 9× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Centrus Energy Corp nearer its low. Which is the better fit depends on your goals.

ABEOLEU
Market Cap
$421.19M$3.77B
Sector
HealthEnergy
52-Week High
$7.45$436.00
52-Week Low
$4.17$146.61
Enterprise Value
$276.10M$3.08B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.

Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.

Centrus Energy Corp

Centrus Energy (LEU) trades at $185.06, down 2.26% on the day, with a bullish technical signal from moving averages and a neutral RSI near 61. The stock shows strong earnings beats in Q1 and Q2 2026 but missed in Q4 2025, with revenue growth to $474 million in 2026. Recent news highlights a $4.5 billion backlog and a $1 billion DOE contract for nuclear fuel supply, positioning the company in the expanding nuclear energy sector.

Outlook is positive due to government support and contract wins, but risks include margin compression and high valuation multiples. Analysts maintain a buy consensus with a $228.50 price target, suggesting 23% upside, though execution on production goals by 2029 is critical for sustained growth.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About Centrus Energy Corp

Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.

Read more on LEU